- Home
- PHAT vs RIGL Comparison
PHAT vs RIGL Comparison
Compare PHAT & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAT
- RIGL
- Stock Information
- Founded
- PHAT 2018
- RIGL 1996
- Country
- PHAT United States
- RIGL United States
- Employees
- PHAT N/A
- RIGL N/A
- Industry
- PHAT Biotechnology: Pharmaceutical Preparations
- RIGL Biotechnology: Pharmaceutical Preparations
- Sector
- PHAT Health Care
- RIGL Health Care
- Exchange
- PHAT Nasdaq
- RIGL Nasdaq
- Market Cap
- PHAT 289.0M
- RIGL 335.5M
- IPO Year
- PHAT 2019
- RIGL 2000
- Fundamental
- Price
- PHAT $4.25
- RIGL $19.20
- Analyst Decision
- PHAT Strong Buy
- RIGL Buy
- Analyst Count
- PHAT 4
- RIGL 5
- Target Price
- PHAT $16.25
- RIGL $36.40
- AVG Volume (30 Days)
- PHAT 2.2M
- RIGL 242.8K
- Earning Date
- PHAT 05-01-2025
- RIGL 05-06-2025
- Dividend Yield
- PHAT N/A
- RIGL N/A
- EPS Growth
- PHAT N/A
- RIGL N/A
- EPS
- PHAT N/A
- RIGL 2.08
- Revenue
- PHAT $81,859,000.00
- RIGL $203,077,000.00
- Revenue This Year
- PHAT $195.45
- RIGL $16.75
- Revenue Next Year
- PHAT $106.76
- RIGL $13.74
- P/E Ratio
- PHAT N/A
- RIGL $9.21
- Revenue Growth
- PHAT 3055.70
- RIGL 70.16
- 52 Week Low
- PHAT $2.21
- RIGL $7.48
- 52 Week High
- PHAT $19.71
- RIGL $29.82
- Technical
- Relative Strength Index (RSI)
- PHAT 54.83
- RIGL 50.40
- Support Level
- PHAT $3.92
- RIGL $18.32
- Resistance Level
- PHAT $4.35
- RIGL $19.91
- Average True Range (ATR)
- PHAT 0.40
- RIGL 1.09
- MACD
- PHAT 0.13
- RIGL -0.04
- Stochastic Oscillator
- PHAT 85.63
- RIGL 42.12
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.